Santhera extends Highbridge convertible bond to 30th September 2025
Globenewswire·2025-08-15 05:00
Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical needs [2] - The company holds an exclusive license for AGAMREE® (vamorolone), a dissociative steroid, for all indications worldwide from ReveraGen [2] - AGAMREE is approved for the treatment of Duchenne muscular dystrophy (DMD) in multiple regions, including the U.S., EU, UK, China, and Hong Kong [2] Recent Developments - Santhera Pharmaceuticals and Highbridge Capital Management have mutually agreed to extend the maturity date of an existing CHF 7 million private convertible bond to 30 September 2025 [1]